iDose implant lowers eye pressure and reduces drop use for glaucoma.
iDose® TR glaucoma implant is a tiny, FDA-approved, sustained-release travoprost implant that lowers eye pressure in open-angle glaucoma and ocular hypertension—helping you stay on track when daily drops are hard to maintain. At Wellish Abrams Vision Institute in Las Vegas, our glaucoma team personalizes candidacy, placement, and follow-up so you know exactly what to expect.
The iDose® TR (travoprost intracameral implant) is a microscopic, anchored device that continuously releases a prostaglandin analog inside the eye to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). It’s placed through a tiny clear-corneal incision with an ab-interno approach and anchors at the iridocorneal angle.
Ideal candidates for iDose include those who: Have been diagnosed with open-angle glaucoma or ocular hypertension — a requirement for this treatment. Struggle with daily eye drops because they forget doses, have difficulty administering them, or experience bothersome side effects. Have trouble staying consistent with prescribed therapy, including patients who have stopped using their drops. They are not achieving adequate eye-pressure control even while using their current medications.
The iDose® TR procedure is a quick, minimally invasive outpatient treatment where a tiny, titanium implant filled with glaucoma medication is placed inside the eye to release medication over time continuously. Your eye is numbed for comfort, and the surgeon uses a small, precise instrument to insert the implant into the trabecular meshwork—the eye’s natural drainage pathway—through a micro-incision. The implant immediately begins delivering medication directly where it’s needed to lower eye pressure. The procedure typically takes only a few minutes, involves little to no discomfort, and most patients resume normal activities within a day or two.
In controlled studies, the most common ocular adverse reactions (about 2–6%) included increased IOP, iritis, dry eye, ocular hyperemia, eye pain, visual-field changes, and reduced visual acuity. Your surgeon will review risks, alternatives, and how we monitor healing
Pivotal trials demonstrated iDose® TR lowered IOP comparably to a standard pressure-lowering regimen in many patients, supporting its use as a long-duration, intracameral prostaglandin therapy when appropriate. We’ll align expectations with your exact diagnosis and target pressure.
Yes. It’s FDA-approved to reduce IOP in adults with OAG or OHT.
Some patients reduce drops; others still use a simplified regimen. Your plan is individualized.
It’s designed for sustained travoprost delivery; your surgeon will discuss the expected duration and follow-up based on your case and current labeling.
Common events include temporary redness, inflammation, or pressure changes; your doctor will counsel you on risks and warning signs.
Per current labeling, iDose TR is not re-administered to an eye that already received it. We’ll discuss long-term planning during your visit.
For full prescribing details, see the FDA-approved label for iDose® TR (travoprost intracameral implant).
Schedule a glaucoma evaluation with Wellish Abrams Vision Institute in Las Vegas. We’ll review candidacy, benefits, risks, and alternatives so you can move forward with confidence.
